赣南医学院学报2018，Vol.38Issue(4)：384-386,3.DOI:10.3969/j.issn.1001-5779.2018.04.021
信必可都保联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)的疗效观察
Curative Effects of Symbicort Turbuhaler Combined with Tiotropium Bromide on Patients with Asthma COPD overlap syndrome (ACOS)
摘要
Abstract
Objective: To observe the therapeutic effects of Symbicort turbuhaler combined with Tiotropium bromide on patients with asthma COPD overlap syndrome(ACOS). Methods: Twenty-eight patients with ACOS were divided into treatment group and control group randomly. The control group was given general treatment of doxofylline and salbutamol inhalation. The treatment group was given Symbicort turbuhaler combined with Tiotropium bromide. All patients were treated continuously for 2 months. Pulmonary function, blood gas analysis of PaO2, PaCO2, 6-min walk test (6MWT) and CRP were measured before and after treatment. Results: Pulmonary function, blood gas analysis and walk test were improved significantly in the treatment group compared with the control group (P＜ 0. 01). Conclusion: Symbicort turbuhaler combined with Tiotropium bromide can significantly improve the pulmonary function and blood oxygen status of patients with ACOS, increase the walking distance. It is beneficial to improve the quality of life and prognosis of patients.关键词
信必可都保/噻托溴铵/哮喘-慢性阻塞性肺疾病重叠综合征Key words
Symbicort turbuhaler/Tiotropium bromide/ACOS分类
医药卫生引用本文复制引用
熊丽娇,王萍,曾治平..信必可都保联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)的疗效观察[J].赣南医学院学报,2018,38(4):384-386,3.基金项目
为2017年度江西省卫生计生委科技项目(编号: 20175342) （编号: 20175342）
